Rate Of Return
Traded Value$Novo Nordisk AS(NVO.US) is hopeless. The world's first oral weight-loss drug was approved, but the stock only rose a little, which shows how little the market thinks of Novo Nordisk. If it drags on until March-June 2026 when Eli Lilly's oral weight-loss drug is approved, NVO will be completely finished.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments